Evaluating Basophil Histamine Content as a Biomarker for Omalizumab Responsiveness in Chronic Spontaneous Urticaria
Summary Our study confirms an association between basophil histamine content and features of type IIb CSU. However, this biomarker is not suitable for predicting omalizumab treatment response or treatment course.
Authors
- Ditte Georgina Zhang (ORCID: https://orcid.org/0000-0003-0742-743X)
- Simon Francis Thomsen (ORCID: https://orcid.org/0000-0002-4838-300X)
- Per Stahl Skov
- Clive Grattan
- Katrine Baumann
Institutions
- University of Copenhagen (DK)
- Guy's Hospital (GB)
- Bispebjerg Hospital (DK)
- Hvidovre Hospital (DK)
- St John's Hospital (GB)
Publication Details
- Journal
- Clinical & Experimental Allergy
- Published
- 2026-04-26
- DOI
- https://doi.org/10.1111/cea.70327
- Primary Topic
- Urticaria and Related Conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00